Forte Biosciences, Inc. (FBRX) intrinsic value & 10-year financials
Forte Biosciences, Inc. (FBRX) has a Graham intrinsic value of $44.86 per share.
- Graham intrinsic value
- $44.86
- Revenue (FY2025)
- —
- Revenue growth (10-yr CAGR)
- -9.8%
- ROIC (10-yr avg)
- -140.1%
- Free cash flow (FY2025)
- -$51.0M
FBRX 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$69.4M | -$4.71 | -$51.0M | — | -124.5% |
| FY2024 | — | -$35.5M | -$12.17 | -$30.8M | — | -83.4% |
| FY2023 | — | -$31.5M | -$1.00 | -$28.8M | — | -84.9% |
| FY2022 | — | -$13.9M | -$0.80 | — | — | -34.5% |
| FY2021 | — | -$21.7M | -$1.55 | — | — | -43.2% |
| FY2020 | — | -$46.5M | — | — | — | -789.4% |
| FY2019 | $36.0K | -$63.5M | — | -$59.7M | -170863.9% | -248.9% |
| FY2018 | $18.0M | -$49.0M | — | -$36.4M | -254.2% | -111.4% |
| FY2017 | $41.0K | -$38.9M | — | -$31.8M | -91778.0% | 93.0% |
| FY2016 | $49.0K | -$33.5M | — | -$30.1M | -64675.5% | 26.5% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Forte Biosciences, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Forte Biosciences, Inc. has historically struggled to out-earn its cost of capital, averaging just -37.3% ROIC.
Forte Biosciences, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Forte Biosciences, Inc. is modeled at -9.8% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $44.86 per share.